VIRX (viracta.com) Return on Gross Profit

Corporate emblem and logo of Viracta Therapeutics, Inc. (VIRX)

The gross margin ratio reflects profit dynamics after deducting the cost of goods sold, with 0.00 serving as the current metric level. Viracta Therapeutics (VIRX) revenues will be based on the commercialization of virus-induced tumor therapies. The business relies on epigenetic virus activation methods to destroy cancer. Management is currently optimizing headcount and expenses while awaiting the verdict on key tests.

Viracta Therapeutics, Inc. (VIRX) - Gross Margin from 07/04/2022 to 02/16/2025

Comprehensive metric breakdowns and analytics for viracta.com (VIRX)

Fundamental valuation:Viracta Therapeutics (VIRX)
Manufactured products of Viracta Therapeutics

Gross margin determines the efficiency of direct cost management by measuring the portion of revenue remaining after deducting the cost of goods sold. An analysis of production margins allows for the tracking of operational pivots through the difference between the selling price and the cost of product manufacturing. For Viracta Therapeutics (VIRX), this indicator is specific in nature, as the absence of regular sales makes it dependent on clinical trial stages.

Direct competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|GDTC: Gross Return on Sales|CRIS: Return on Gross Profit|apollomicsinc.com (APLM) - Return on Gross Profit|THAR: Gross Margin|Return on Gross Profit Advanced Biomed Inc.|Return on Gross Profit GNPX|Gross Return on Sales CLDI (Calidi Biotherapeutics)|Gross Margin SBFM|Xenetic Biosciences, Inc. - Gross Return on Sales|Gross Profitability Salarius Pharmaceuticals SLRX|Gross Margin purple-biotech.com PPBT|AONC - Gross Profitability|BGNE: Gross Profitability|CKPT: Gross Margin|Elevation Oncology - Gross Profit Rate|ICAD (iCAD) - Gross Margin|IKNA: Gross Profit Rate|Gross Profitability Notable Labs (NTBL)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit